Latest News and Press Releases

ZURICH, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF, SIX: ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), would like to invite investors and shareholders to a...

ZURICH, Switzerland, June 20, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that...

ZURICH, Switzerland, June 06, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that...

Buranto AG Provided a USD$260,000 (CHF 250,000) Loan Facility and Existing Strategic Investor Negma Group Provided a USD$1.04 Million (CHF 1.0 Million) Loan FacilityDerek Brandt, Co-owner of Buranto...

ZURICH, Switzerland, April 29, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that...

The chemical mode of action of AptameX, Achiko's rapid Covid-19 test, strongly suggests that Omicron can be detected as reliably as any other Covid-19 variant known to dateAchiko’s highly effective,...

Achiko to develop dengue fever diagnostic test by applying its DNA aptamer technology platform. This is another promising application of the technology that Achiko is already successfully using to...

Achiko has received its first purchase order in Jakarta and Bali in Indonesia.The orders translate to 20,000 tests - while modest in size, the order is expected to pave the way to rapid adoption by...

Launch of pilot program in Indonesia for Achiko’s proprietary, low-cost rapid Covid-19 diagnostic test, AptameX, alongside its sister digital passporting service, Teman Sehat (“Health Buddy”).Purpose...